Review

deidentified sequencing data (Caris Life Sciences)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Caris Life Sciences deidentified sequencing data
Deidentified Sequencing Data, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/deidentified+sequencing+data/data+deidentified+sequencing/pm42236117-372-1-7
Average 86 stars, based on 1 article reviews

deidentified sequencing data - by Bioz Stars, 2026-10

86/100 stars

Images

Sequencing:

Article Title: Molecular Characterization of <i>KLK2</i> RNA Expression in Prostate Cancer
Article Snippet: 250 words): 237 Purpose: KLK2 is an androgen-regulated gene critical in prostate cancer biology with multiple KLK2-targeted therapies in clinical development.. We investigated KLK2 RNA expression patterns and associations with molecular features to provide context for emerging KLK2-targeted treatments.. Experimental Design: DNA/RNA next-generation sequencing was performed on 7,078 prostate cancer specimens.

Article Title: Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program
Article Snippet: .. The deidentified sequencing data are owned by Caris Life Sciences and cannot be publicly shared due to the data usage agreement. ..

Article Title: Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications
Article Snippet: .. The deidentified sequencing data are owned by Caris Life Sciences. ..

Article Title: Multiomic characterization of small cell lung cancer: Real‐world insights into therapeutic opportunities
Article Snippet: .. The deidentified sequencing data are owned by Caris Life Sciences, and qualified researchers can apply for access by signing a data usage agreement. ..

Article Title: Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy
Article Snippet: .. Caris Life Sciences owns the deidentified sequencing data, which cannot be publicly shared due to the data usage agreement in place. ..

Article Title: Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy Sensitivity
Article Snippet: .. The deidentified sequencing data and corresponding clinical parameters analyzed in this report are owned by Caris Life Sciences. ..

Article Title: Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.
Article Snippet: .. The deidentified sequencing data is owned by Caris Life Sciences and cannot be publicly shared due to the data usage agreement in place. .. The GSEA software is publicly available from the Broad Institute of MIT and Harvard University (http://software.broadinstitute.org/gsea/index.jsp).

Article Title: Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy.
Article Snippet: .. Caris Life Sciences owns the deidentified sequencing data, which cannot be publicly shared due to the data usage agreement in place. ..

Image Search Results

A) SKBR3 shFLOT2 or shControl were pretreated with DMSO control (black) or 500 ng/mL doxycycline (gray) for 48 hours in 1% FBS RPMI, then treated with indicated T-DM1 concentration with continued doxycycline in 1% FBS RPMI for three days prior to cell counting. The table below the graphs indicates the calculated IC50 comparing DMSO + T-DM1 to doxycycline + T-DM1. Data represents the average ±SEM of at least three independent experiments, and statistical analysis was performed by Student’s t-test. B) Same as in A, with HCC202 shFLOT2 or shControl. C) Same as in A, with HCC1954 shFLOT2 or shControl. D) ARK1 (top) or ARK2 (bottom) cells were transfected with siNeg (black) or siFLOT2 (gray) for 48 hours prior to being treated with indicated T-DM1 concentration in 10% FBS RPMI for three days prior to cell viability reading (CellTiter-Glo 2.0). Data represents the average ±SEM of at least three independent experiments, and statistical analysis was performed by Student’s t-test. E) SKBR3, HCC202, HCC1954, BT474, HCC1419, HCC2218, UACC893, ARK1, and ARK2 cells were treated with 0-1000 ng/mL T-DM1 in 1% FBS RPMI for three days prior to cell counting. Average FLOT2 expression by immunoblot (relative to HSC70 loading control) and the calculated IC50 for each cell line was plotted. Protein expression and IC50 were calculated from at least three independent experiments. Line represents linear regression. F) Same as E, with average HER2 expression (relative to HSC70 loading control). G) Overall survival of patients in Caris dataset from T-DXd to last contact with high FLOT2 (orange; 16.22 months) vs low FLOT2 (blue; 18.26 months), p=0.041. H) Overall survival of patients in Caris dataset from T-DM1 to last contact with high FLOT2 (orange; 37.967 months) vs low FLOT2 (blue; 41.29 months), p=0.131.

Journal: bioRxiv

Article Title: Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers

doi: 10.64898/2026.05.15.725439

Figure Lengend Snippet: A) SKBR3 shFLOT2 or shControl were pretreated with DMSO control (black) or 500 ng/mL doxycycline (gray) for 48 hours in 1% FBS RPMI, then treated with indicated T-DM1 concentration with continued doxycycline in 1% FBS RPMI for three days prior to cell counting. The table below the graphs indicates the calculated IC50 comparing DMSO + T-DM1 to doxycycline + T-DM1. Data represents the average ±SEM of at least three independent experiments, and statistical analysis was performed by Student’s t-test. B) Same as in A, with HCC202 shFLOT2 or shControl. C) Same as in A, with HCC1954 shFLOT2 or shControl. D) ARK1 (top) or ARK2 (bottom) cells were transfected with siNeg (black) or siFLOT2 (gray) for 48 hours prior to being treated with indicated T-DM1 concentration in 10% FBS RPMI for three days prior to cell viability reading (CellTiter-Glo 2.0). Data represents the average ±SEM of at least three independent experiments, and statistical analysis was performed by Student’s t-test. E) SKBR3, HCC202, HCC1954, BT474, HCC1419, HCC2218, UACC893, ARK1, and ARK2 cells were treated with 0-1000 ng/mL T-DM1 in 1% FBS RPMI for three days prior to cell counting. Average FLOT2 expression by immunoblot (relative to HSC70 loading control) and the calculated IC50 for each cell line was plotted. Protein expression and IC50 were calculated from at least three independent experiments. Line represents linear regression. F) Same as E, with average HER2 expression (relative to HSC70 loading control). G) Overall survival of patients in Caris dataset from T-DXd to last contact with high FLOT2 (orange; 16.22 months) vs low FLOT2 (blue; 18.26 months), p=0.041. H) Overall survival of patients in Caris dataset from T-DM1 to last contact with high FLOT2 (orange; 37.967 months) vs low FLOT2 (blue; 41.29 months), p=0.131.

Article Snippet: The Caris deidentified sequencing data are owned by Caris Life Sciences and cannot be publicly shared due to the data usage agreement in place.

Techniques: Control, Concentration Assay, Cell Counting, Transfection, Expressing, Western Blot